The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer
Status:
Recruiting
Trial end date:
2025-05-31
Target enrollment:
Participant gender:
Summary
This research study is studying a combination of drugs as a possible treatment for breast
cancer.
The drugs involved in this study are:
- Group A: Trastuzumab (Herceptin) + Vinorelbine (Navelbine)
- Group B: Trastuzumab + Vinorelbine + Avelumab
- Group C: Trastuzumab + Vinorelbine + Avelumab + Utomilumab (PF-05082566)
Phase:
Phase 2
Details
Lead Sponsor:
Ian E. Krop, MD, PhD
Collaborators:
Breast Cancer Research Foundation Johns Hopkins University Pfizer